News - Eli Lilly, Pricing

Filter

Current filters:

Eli LillyPricing

Popular Filters

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Eli Lilly to expand manufacturing plants in Brazil’s growing pharma market

Eli Lilly to expand manufacturing plants in Brazil’s growing pharma market

03-03-2014

US pharma major Eli Lilly’s subsidiary in Brazil will invest 15 million real ($6.4 million) over the…

BrazilEli LillyPharmaceuticalPricingProductionSouth America

Negative NICE appraisal for Eli Lilly’s Alimta as maintenance therapy

27-02-2014

UK health care guidance body the National Institute for Health and Care Excellence (NICE) has published…

AlimtaEli LillyNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

14-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund paliperidone…

Eli LillyHealthcareInvega SustennaJohnson & JohnsonNeurologicalNew ZealandPharmaceuticalPricingRisperdal ConstaZyprexa Relprevv

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats

26-06-2013

An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

NICE final draft guidance on Eli Lilly's Alimta negative

13-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (June 13)…

AlimtaEli LillyEuropeOncologyPharmaceuticalPricingRegulation

NICE draft guidance rejects Eli Lilly's Alimta for NSCLC maintenance

22-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

AlimtaEli LillyEuropeOncologyPharmaceuticalPricingRegulation

Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG

13-12-2012

Once again, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found no added…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalPricingRegulationTrajenta

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

Lilly CEO calls for a health care policy environment that promotes medical innovation

07-06-2012

Regardless of how the Supreme Court rules on the Affordable Care Act, US drug major Eli Lilly (NYSE:…

Eli LillyPharmaceuticalPoliticsPricingResearch

New Zealand approves Effient listing for clopidogrel-allergic patients

19-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

UK NICE says yes to Lilly’s Bydureon and ALK-Abello’s Pharmalgen

22-02-2012

The UK’s health care guidance body the National Institute for Health and Clinical Excellence (NICE),…

ALK AbelloBydureonDiabetesEli LillyEuropePharmaceuticalPharmalgenPricingRegulationRespiratory and Pulmonary

Proposal to fund Lilly’s Effient in New Zealand

21-02-2012

PHARMAC, the Pharmaceutical Management Agency of New Zealand, is seeking feedback on a proposal to fund…

Asia-PacificEffientEli LillyPharmaceuticalPricingRegulation

Mixed NICE recommendations for CML and diabetes drugs

13-01-2012

In a batch of final guidances released this morning by the UK’s drug watchdog the Institute for…

Bristol-Myers SquibbBydureonDiabetesEli LillyEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

UK NICE draft guidance recommends Eli Lilly’s Bydureon for type 2 diabetes

18-10-2011

The UK drugs watchdog the National Institute of Health and Clinical Excellence (NICE) today published…

BydureonDiabetesEli LillyEuropePharmaceuticalPricingRegulation

Pfizer’s Pristiq sees private plan formulary access similar to Lilly’s Cymbalta

31-08-2011

In the USA, similar percentages of private health plan lives have formulary access to Pfizer’s (NYSE:…

CymbaltaEli LillyHealthcareNeurologicalNorth AmericaPfizerPharmaceuticalPricingPristiq

Back to top